ArticleBone2020

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

Kathryn M Thrailkill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.